Tennis anyone? The lungs as a new court for systemic therapy

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 10, 1999, Pages 1287-1288

  Newhouse, Michael T ^a,b,c   Strand, Joyce ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CALCITONIN; GROWTH HORMONE; INSULIN; PANCREAS ENZYME; PEPTIDE; PROTEIN;

AEROSOL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG GAS EXCHANGE; MACROMOLECULE; MEMBRANE PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RESPIRATORY AIRFLOW; SHORT SURVEY; TIDAL VOLUME; TOTAL LUNG CAPACITY; TRANSCYTOSIS;

EID: 0033576322     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. 1. Mackay M, Phillips J, Steward A, Hastewell J. Pulmonary absorption of therapeutic peptides and proteins. In: Proceedings of Respiratory Drug Delivery IV; 1994 May; Buffalo Grove (IL): Interpharm Press; 1994. p. 31-7.
2. 2. Folkesson HG, Westrom BR, Karlsson BW. Permeability of the respiratory tract to different-sized macromolecules arter intratracheal instillation in young and adult rats. Acta Physiol Scand 1990;139:347-54.
3. 3. Adjeji AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997.
4. 4. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995;12(2-3):151-231.
5. 5. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3-36.
6. 6. Skyler JS, Gelfand RA, Kourides IA, for the Inhaled Insulin Phase II Study Group. Treatment of type 1 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial [abstract 236]. Diabetes 1998;47(Suppl 1):A61.
7. 7. Cefalu WT, Gelfand RA, Kourides I, for the Inhaled Insulin Phase II Study Group. Treatment of type 2 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial [abstract 237]. Diabetes 1998;47(Suppl 1):A61.
8. 8. Berger S, Davidson MH, Kourides I, Landschulz WH, Gelfand RA, for the Inhaled Insulin Phase II Study Group. Add-on therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: preliminary results of a multicenter trial [abstract]. European Association for the Study of Diabetes meeting; 1998 Sept.; Barcelona.
9. 9. Threshold limit values for chemical substances and physical agents and biological exposure indices, 1992-1993 [pamphlet]. Cincinnati: American Conference of Governmental Industrial Hygienists, Technical Information Office; 1992.